Empagliflozin improves cardiac function through the increased production of acetylcarnitine in a murine non-diabetic heart failure model

被引：0
|
作者：
Nakao, M. [1 ]
Shimizu, I. [2 ]
Yoshida, Y. [2 ]
Katsuumi, G. [1 ]
Hayashi, Y. [1 ]
Ikegami, R. [1 ]
Suda, M. [1 ]
Wakasugi, T. [1 ]
Minamino, T. [1 ]
机构：
[1] Niigata Univ, Grad Sch Med & Dent Sci, Dept Cardiovasc Biol & Med, Niigata, Japan
[2] Niigata Univ, Grad Sch Med & Dent Sci, Div Mol Aging & Cell Biol, Grad Sch Med & Dent, Niigata, Japan
来源：
EUROPEAN HEART JOURNAL | 2019年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P3496
引用
收藏
页码：2109 / 2109
页数：1
相关论文
共 50 条
  • [31] Inhibiting Fibronectin Improves Cardiac Function in a Mouse Model of Heart Failure
    Valiente-Alandi, Inigo
    Nieman, Michelle
    Blaxall, Burns C.
    CIRCULATION RESEARCH, 2016, 119
  • [32] Inhibiting Fibronectin Improves Cardiac Function in a Mouse Model of Heart Failure
    Alandi, Inigo Valiente
    Nieman, Michelle
    Molkentin, Jeffery D.
    Blaxall, Burns C.
    FASEB JOURNAL, 2016, 30
  • [33] Renal Denervation Improves Cardiac Function in a Swine Model of Heart Failure
    Sharp, Tom, III
    Polhemus, David
    Li, Zhen
    Spaletra, Pablo
    Reilly, John
    Jenkins, James
    White, Christopher
    Lefer, David
    Goodchild, Traci
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (13) : B14 - B14
  • [34] Renal Denervation Improves Cardiac Function in a Swine Model of Heart Failure
    Spaletra, Pablo
    Scarborough, Amy L.
    Boisvert, Sarah F.
    Prejean, Elizabeth L.
    Schumacher, Jeffrey D.
    Reilly, John P.
    Jenkins, Steven J.
    Lefer, David J.
    Goodchild, Traci T.
    CIRCULATION, 2017, 136
  • [35] Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure
    Christiane E. Angermann
    Carlos G. Santos-Gallego
    Juan Antonio Requena-Ibanez
    Susanne Sehner
    Tanja Zeller
    Louisa M. S. Gerhardt
    Christoph Maack
    Javier Sanz
    Stefan Frantz
    Valentin Fuster
    Georg Ertl
    Juan J. Badimon
    Nature Cardiovascular Research, 2023, 2 : 1032 - 1043
  • [36] Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure
    Angermann, Christiane E.
    Santos-Gallego, Carlos G.
    Requena-Ibanez, Juan Antonio
    Sehner, Susanne
    Zeller, Tanja
    Gerhardt, Louisa M. S.
    Maack, Christoph
    Sanz, Javier
    Frantz, Stefan
    Fuster, Valentin
    Ertl, Georg
    Badimon, Juan J.
    NATURE CARDIOVASCULAR RESEARCH, 2023, 2 (11): : 1032 - +
  • [37] Increased urine output by ipragliflozin in a non-diabetic patient with a diuretic-resistant heart failure
    Sairaku, Akinori
    Nakano, Yukiko
    Kihara, Yasuki
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 180 : 42 - 43
  • [38] Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH
    Perakakis, Nikolaos
    Chrysafi, Pavlina
    Feigh, Michael
    Veidal, Sanne Skovgard
    Mantzoros, Christos S.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (12)
  • [39] Short- and Long-Term Empagliflozin Treatment Improves Cardiac Function in Rats with Chronic Heart Failure
    Soulie, Matthieu
    Stephan, Yohan
    Nicol, Lionel
    Henry, Jean-Paul
    Richard, Vincent
    Pieper, Michael
    Mulder, Paul
    DIABETES, 2020, 69
  • [40] Chronic Central Leptin Infusion Improves Cardiac Function in Diabetic Rats With Heart Failure
    da Silva, Alexandre A.
    Gava, Fabio N.
    Lataro, Renata M.
    Silva, Carlos Alberto A.
    Rodrigues, Driell P.
    Guida, Tamires
    do Carmo, Jussara M.
    Salgado, Helio C.
    FASEB JOURNAL, 2017, 31
12345